Shenzhen – September 27, 2026 -- Memory and storage executives from Samsung, Sandisk, Solidigm, Arm and Lenovo converged in Shenzhen on September 23 to argue that AI inference workloads, not training alone, are now the primary driver reshaping storage architecture demand. The 5th GMIF2026 Innovation Summit, co-hosted by the Shenzhen Memory Industry Association (SMIA) and Peking University's School of Integrated Circuits, drew IDMs, controller makers, OSATs, and AI infrastructure vendors under the theme "The Future Built on AI Memory and Storage."

Shanghai – September 26, 2026 -- IASO Biotechnology reported a 90% objective response rate and 90% minimal residual disease (MRD) negativity rate for its BCMA-targeted in vivo CAR-T therapy IASO206, generated via a single intravenous infusion without lymphodepleting chemotherapy, in first-in-human Phase 1 data presented as a late-breaking oral session (LBA-11) at the 2026 International Myeloma Society Annual Meeting.

Shanghai – September 26, 2026 -- IASO Biotechnology's CAR-T therapy FUCASO achieved a 95.9% objective response rate and 77.2% complete/stringent complete response rate in a real-world study of 281 heavily pretreated Chinese patients with relapsed or refractory plasma cell neoplasms, data presented at the 2026 International Myeloma Society Annual Meeting show.

NEW YORK – September 26, 2026 -- China Southern Airlines marked its 70th anniversary with a Times Square display, coinciding with the Mid-Autumn Festival, as the Guangzhou-based carrier reported a fleet of 972 aircraft and 174 million passengers carried in 2025.

Shanghai – September 25, 2026 -- IASO Biotechnology reported an 88.9% objective response rate for its dual-targeted CAR-T therapy RD140 in a first-in-human Phase 1 trial of nine heavily pretreated multiple myeloma and plasma cell leukemia patients, with the response rate reaching 100% in the higher-dose cohort.

Shanghai – September 25, 2026 -- A retrospective analysis of 102 multiple myeloma patients treated with IASO Bio's FUCASO CAR-T therapy found that patients maintaining sustained minimal residual disease (MRD) negativity showed a median CAR-T cell persistence of 463 days, compared with 272 days in patients who experienced MRD conversion — a gap of roughly 191 days. The data, drawn from the pivotal FUMANBA-1 registration study, were presented as a poster (Abstract No. PA-469) at the 2026 International Myeloma Society Annual Meeting.

Guangzhou – September 25, 2026 -- GAC Group's electric drive project has won the Gold Medal with the Congratulations of the Jury, the highest distinction at the 51st International Exhibition of Inventions Geneva, an award requiring unanimous jury approval selected from among all Gold Medal winners.

Singapore – September 25, 2026 -- Brightray Veridian Pte. Ltd., a wholly owned subsidiary of Brightray Science Inc., has signed a Prefabricated Module Sales Framework Agreement with a Macao-based developer for a planned 40MW artificial intelligence data center in Coloane, Macao, with delivery targeted for the third quarter of 2027.

Bad Homburg, Germany – September 25, 2026 -- Fresenius Medical Care will exit its peritoneal dialysis business in China and discontinue local production and sales of its 4008A hemodialysis system, triggering one-time costs of approximately €110 million in the third quarter of 2026.

The charge, tied to impairment, scrappage and termination costs, will be treated as a special item and is not expected to meaningfully affect the future revenue outlook for the China business within the Company's Care Enablement segment.

Shanghai – September 25, 2026 -- Nutshell Therapeutics (Shanghai) Co., Ltd. has received FDA clearance of its Investigational New Drug (IND) application for NTS231, a covalent allosteric molecular glue degrader targeting NRF2, allowing the company to begin clinical development in the United States. NTS231 is the first NRF2 degrader originating from China and only the second such molecule worldwide to reach clinical-stage development.